近年来，免疫疗法的研究集中在嵌合抗原受体修饰的T细胞（CAR-T细胞）上。CAR-T疗法已在临床上应用于管理血液恶性肿瘤，取得了令人满意的疗效。然而，CAR-T免疫疗法在实体肿瘤中的应用仍然具有挑战性。尽管如此，目前用于前列腺癌（PCa）的CAR-T免疫疗法显示出一定的希望，给患有晚期转移性PCa的患者带来了希望。本综述旨在阐明不同类型的前列腺肿瘤相关抗原靶点，如前列腺特异性膜抗原和前列腺干细胞抗原，以及它们的效果。还讨论了临床研究中相关靶点的当前状态，通过它们的应用。为了提高CAR-T免疫疗法的疗效，我们探讨了多模式免疫疗法、化疗和CAR-T联合疗法的可能应用。对实体肿瘤的障碍进行了简明扼要的阐述。进一步的研究应该旨在发现新的潜在靶点，并通过克服实体肿瘤固有的障碍，如肿瘤异质性和肿瘤微环境的免疫抑制性，建立新的模型。© 2023年作者

Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells (CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic malignancies with satisfactory effectiveness. However, the application of CAR-T immunotherapy in solid tumors remains challenging. Even so, current CAR-T immunotherapies for prostate cancer (PCa) have shown some promise, giving hope to patients with advanced metastatic PCa. This review aimed to elucidate different types of prostate tumor-associated antigen targets, such as prostate-specific membrane antigen and prostate stem cell antigen, and their effects. The current status of the corresponding targets in clinical research through their applications was also discussed. To improve the efficacy of CAR-T immunotherapy, we addressed the possible applications of multimodal immunotherapy, chemotherapy, and CAR-T combined therapies. The obstacles of solid tumors were concisely elaborated. Further studies should aim to discover novel potential targets and establish new models by overcoming the inherent barriers of solid tumors, such as tumor heterogeneity and the immunosuppressive nature of the tumor microenvironment.© 2023 The Authors.